Tivity Health (TVTY) Receiving Favorable Press Coverage, Study Shows

News headlines about Tivity Health (NASDAQ:TVTY) have trended positive this week, according to Accern. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Tivity Health earned a news sentiment score of 0.32 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 48.8542408259609 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

A number of research analysts have recently issued reports on TVTY shares. Zacks Investment Research upgraded shares of Tivity Health from a “hold” rating to a “buy” rating and set a $44.00 target price for the company in a research note on Thursday, January 25th. Cantor Fitzgerald restated an “overweight” rating and issued a $53.00 price objective on shares of Tivity Health in a research report on Friday, February 23rd. Barrington Research boosted their price objective on shares of Tivity Health from $40.00 to $47.00 and gave the stock an “outperform” rating in a research report on Friday, February 23rd. BidaskClub upgraded shares of Tivity Health from a “hold” rating to a “buy” rating in a research report on Tuesday, March 6th. Finally, Chardan Capital restated a “neutral” rating and issued a $41.00 price objective (down previously from $44.00) on shares of Tivity Health in a research report on Friday, February 23rd. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $47.11.

Tivity Health opened at $38.25 on Friday, MarketBeat Ratings reports. Tivity Health has a fifty-two week low of $29.95 and a fifty-two week high of $48.50. The company has a market capitalization of $1.54 billion, a P/E ratio of 22.77, a P/E/G ratio of 1.63 and a beta of 0.31.

Tivity Health (NASDAQ:TVTY) last posted its quarterly earnings data on Monday, April 23rd. The company reported $0.49 earnings per share for the quarter, hitting the consensus estimate of $0.49. Tivity Health had a net margin of 12.33% and a return on equity of 28.62%. The firm had revenue of $149.90 million during the quarter, compared to analysts’ expectations of $154.32 million. During the same quarter in the previous year, the company posted $0.42 EPS. Tivity Health’s revenue was up 6.3% on a year-over-year basis. analysts expect that Tivity Health will post 2.16 earnings per share for the current fiscal year.

In other Tivity Health news, CEO Donato Tramuto sold 20,000 shares of Tivity Health stock in a transaction on Tuesday, May 1st. The shares were sold at an average price of $35.37, for a total transaction of $707,400.00. Following the completion of the sale, the chief executive officer now owns 149,596 shares of the company’s stock, valued at approximately $5,291,210.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 60,000 shares of company stock valued at $2,264,000 in the last ninety days. Company insiders own 8.42% of the company’s stock.

About Tivity Health

Tivity Health, Inc provides fitness and health improvement programs in the United States. The company offers SilverSneakers senior fitness program to the members of Medicare advantage, Medicare supplement, and group retiree plans; and Prime fitness, a fitness facility access program through commercial health plans and employers.

Insider Buying and Selling by Quarter for Tivity Health (NASDAQ:TVTY)

Receive News & Ratings for Tivity Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tivity Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply